Completed
OBSERVATIONAL
NCT00934063
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This observational study is conducted in Europe. The aim of this observational study is to investigate the changes in a score (GET-score) which includes quality of life, body composition and cholesterol metabolism in patients on growth hormone treatment. The GET score stands for: Growth hormone deficiency and Efficacy of Treatment, and is a quantitative measurement of the efficacy of the treatment with growth hormone in adults.
Interventions
Name:
somatropin
Type:
DRUG
Description:
For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Name:
No treatment given
Type:
OTHER
Description:
Control group not receiving treatment
Primary Outcomes
Measure:
Improvement of an integrated score which consists of Quality of Life (QoL), body composition, lipid metabolism, bone mineral density
TimeFrame:
at 0, 3, 6, 12, 18 and 24 months after treatment initiation
Description:
Trial Information
NCT ID
NCT00934063
Status
Completed
Study Type
OBSERVATIONAL
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025